Viromed Medical AG Stock
Price
Target price
€7.20
€7.20
3.500%
0.25
3.500%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Viromed Medical
sharewise wants to provide you with the best news and tools for Viromed Medical, so we directly link to the best financial data sources.
Financials
News
EQS-News: Viromed Medical AG: Study on Cold Plasma Application in the Lung Successfully Completed
EQS-News: Viromed Medical AG: Study on Cold Plasma Application in the Lung Successfully Completed
EQS-News: Viromed Medical AG significantly increases consolidated revenue in the 2025 financial year and achieves a positive net income
EQS-News: Viromed Medical AG significantly increases consolidated revenue in the 2025 financial year and achieves a positive net income
EQS-News: Viromed Medical AG signs exclusive distribution partnership with NEBU-TEC for PulmoPlas® with a focus on veterinary applications
EQS-News: Viromed Medical AG signs exclusive distribution partnership with NEBU-TEC for PulmoPlas® with a focus on veterinary applications
EQS-News: Viromed Medical AG: ViroCAP® med successfully completes regulatory process as a Class IIa medical device – starting signal for market launch at the European Wound Congress 2026
EQS-News: Viromed Medical AG: ViroCAP® med successfully completes regulatory process as a Class IIa medical device – starting signal for market launch at the European Wound Congress 2026
EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
EQS-News: Viromed Medical AG starts production of the OEM version of ViroCAP® for HELLMUT RUCK GmbH
EQS-News: Viromed Medical AG starts production of the OEM version of ViroCAP® for HELLMUT RUCK GmbH
EQS-News: Viromed Medical AG receives funding approval from the Federal Ministry of Research, Technology and Space for the development of cold plasma technology
EQS-News: Viromed Medical AG receives funding approval from the Federal Ministry of Research, Technology and Space for the development of cold plasma technology
EQS-News: Viromed Medical AG: Anna Heinen appointed to the Supervisory Board
EQS-News: Viromed Medical AG: Anna Heinen appointed to the Supervisory Board
EQS-News: Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH – Strategic step toward integrated platform for cold plasma technology
EQS-News: Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH – Strategic step toward integrated platform for cold plasma technology
EQS-Adhoc: Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH
EQS-Adhoc: Viromed Medical AG signs letter of intent to acquire relyon plasma GmbH
EQS-News: MHH to Present Scientific Findings on Cold Plasma Therapy for Pulmonary Application at Press Conference in February 2026
EQS-News: MHH to Present Scientific Findings on Cold Plasma Therapy for Pulmonary Application at Press Conference in February 2026
EQS-News: Correction of a release from 19/01/2026, 11:45 CET/CEST - Viromed Medical AG: Ex-vivo lung study marks milestone for research and approval
EQS-News: Correction of a release from 19/01/2026, 11:45 CET/CEST - Viromed Medical AG: Ex-vivo lung study marks milestone for research and approval
EQS-News: Viromed Medical AG: Ex-vivo lung study marks milestone for research and approval
EQS-News: Viromed Medical AG: Ex-vivo lung study marks milestone for research and approval